NCT04436471View on ClinicalTrials.gov

"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug Gam-COVID-Vac Vaccine Against COVID-19"

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 17, 2020

Primary Completion Date

August 3, 2020

Study Completion Date

August 10, 2020

Conditions
Preventive Immunization COVID-19
Interventions
BIOLOGICAL

Gam-COVID-Vac

adenoviral-based vaccine against SARS-CoV-2

Trial Locations (1)

Unknown

Main military clinical hospital named after academician N. N. Burdenko, Moscow

Sponsors
All Listed Sponsors
collaborator

Acellena Contract Drug Research and Development

OTHER

lead

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

OTHER